The RTK, FGFR2 and the phosphatase, SHP2 are targeted with existing drugs ... Fibroblast growth factor receptor 2 (FGFR2) is a receptor tyrosine kinase that can be amplified in gastric cancer and ...

论文题为“Multiple receptor tyrosine kinase activation attenuates therapeutic efficacy of the fibroblast growth ...

Conclusion: The tyrosine kinase inhibitors sorafenib and sunitinib offer improved outcomes for patients with mRCC, but they are far short of a cure. Despite the introduction of sorafenib and ...

Imatinib was chosen as a standard drug due to its established efficacy as a tyrosine kinase inhibitor in the treatment of chronic myeloid leukemia ... and site of ligand and binding affinity between ...